Fluoroestradiol F18 and Breastfeeding

Summary of use during lactation

Information in this record refers to the use of fluoroestradiol F18 (18F-FES) as a diagnostic agent. No information is available on the clinical use of fluoroestradiol F18 during breastfeeding. The manufacturer recommends that mothers avoid breastfeeding for 4 hours after administration of fluoroestradiol F18. Nursing mothers should not work with radioactive substances used in PET scans in their workplace.[1]

Drug levels in milk and infant serum

F18 is a positron emitter with a principal decay energy of 0.6335 MeV, annihilation photons of 0.511 MeV, and a physical half-life of 1.8 hours and 0.07% of an administered dose appears in breastmilk.[2] The maximum effective half-life is 0.89 hours.[3] Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

References

1. AlménA MattssonS Radiological protection of foetuses and breast-fed children of occupationally exposed women in nuclear medicine - Challenges for hospitals. Phys Med 2017 43 172 7 28882410 PubMed
2. Leide-SvegbornS AhlgrenL JohanssonL Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption. Eur J Nucl Med Mol Imaging 2016 43 808 21 26732471 PubMed
3. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. https://www.gov.uk/government/publications/arsac-notes-for-guidance